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Prosultiamine 300 mg was given orally once daily for 12 weeks. As a result, improvement in the motor function of the lower extremities based on a reduction in spasticity (e.g. decrease in time required for walking and descending a flight of stairs) was observed. Interestingly, this treatment induced the striking amelioration of urinary disturbance. In an urodynamic study (UDS), bladder capacity and detrusor pressure, and then maximum flow rate, increased significantly. Detrusor overactivity and detrusor-sphincter dyssynergia improved in 68.8% and 45.5% of patients, respectively. Improvement in UDS corresponded with improvements in the score of nocturia quality of life questionnaire. Thus, given that the mean duration of illness of the patients enrolled in the present study was relatively long (approximately 21 years), the efficacy of this treatment is promising.
In the present study, HTLV-I proviral copy numbers in PBMC decreased significantly (approximately 15.4%) compared with pretreatment levels. However, the remarkable clinical improvement in the present study cannot be attributed solely to a decrease in HTLV-I proviral copy numbers in PBMC. Although the exact mechanism is not known, it might be conceivable that, as one of the mechanisms, prosultiamine functions to induce the apoptosis of HTLV-Iinfected cells by the disruption of intracellular redox system in the spinal cord, even if the extent of reduction of the number of HTLV-I-infected cells in PBMC is relatively small. Further investigations including analysis of cerebrospinal fluid are required to elucidate the exact mechanism of action of prosultiamine.
Overall, the present results suggest that prosultiamine could be a new promising therapeutic tool for HAM/TSP patients. Therefore, further studies are warranted for the evaluation of prosultiamine treatment against HAM/TSP in a large-scale, randomized, controlled study and long-term treatment.
